Tag: Genetic obesity

According to the World Health Organization, the percentage of overweight or obese individuals aged 5-19 years increased from 4% in 1975 to 18% in 2016, highlighting the need for targeted therapies. For specific and rare genetic forms of obesity, the precise answer to the question, what is the classification of setmelanotide?, reveals its role as a targeted, precision medicine.

Rare genetic disorders are responsible for an estimated 40-70% of an individual's predisposition to obesity. For some of these conditions, a key question is: **what type of drug is setmelanotide?** It is a first-in-class melanocortin 4 (MC4) receptor agonist designed to address the root cause of insatiable hunger.